Marideli Scanlan, MD
Endocrinology, Diabetes & Metabolism · Marrero, LANPI 1205027349
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $373,482 of the $444,321 with a category attached, or 84.1%. 43 manufacturers reported payments, led by Novo Nordisk at 45.2% of the total. Among endocrinology, diabetes & metabolism clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,002 payments — averaging $443.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$201K
- Lilly USA, LLC$127K
- Dexcom, Inc.$67K
- Boehringer Ingelheim$26K
- AstraZeneca$17K
- Amgen$780
- plus $5K from 37 others
Across 5 payments — averaging $343.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$2K
What the payments were for
- Consulting fees$4880%
- Speaking & faculty fees$373,48284%
- Travel & lodging$49,63611%
- Food & beverage$20,5995%
- Education$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$111,878
- MOUNJARO$102,789
- RYBELSUS$59,330
- DEXCOM G7 GSS (161)$49,522
- JARDIANCE$35,165
- FARXIGA$16,867
- Tresiba$16,323
- DEXCOM G6 TRANSMITTER$12,142
- DEXCOM STELO GLUCOSE BIOSENSOR$6,434
- Xultophy 100/3.6$4,878
- DEXCOM G6 CGM SYSTEM$3,826
- iLet Bionic Pancreas$1,861
- Korlym$228
- DEXCOM CGM$136
- iLet Insulin Infusion Kit Inset$132
- iLet Insulin Infusion Kit Contact Detach$132
- Kerendia$125
- TEPEZZA$125
- INVOKANA$124
- Vascepa$123
How this compares
$444,321 in reported general payments places this provider in the 95th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 335 | $470,177 |
| MounjaroTirzepatide | 128 | $150,759 |
| JardianceEmpagliflozin | 85 | $107,259 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 49 | $54,994 |
| Repatha SureclickEvolocumab | 54 | $40,997 |
| TrulicityDulaglutide | 24 | $38,207 |
| Symlinpen 120Pramlintide Acetate | 13 | $30,367 |
| TradjentaLinagliptin | 18 | $23,657 |
| JanuviaSitagliptin Phosphate | 13 | $15,564 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $15,028 |
| FarxigaDapagliflozin Propanediol | 22 | $12,311 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $10,426 |
| LevoxylLevothyroxine Sodium | 167 | $9,291 |
| XyostedTestosterone Enanthate | 12 | $7,620 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 35 | $6,458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $200,674 | $470,177335 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $127,420 | $192,581168 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $26,091 | $185,911152 claims |
| MerckJanuvia | $144 | $15,56413 claims |
| AstraZenecaFarxiga | $17,460 | $12,31122 claims |
| PfizerLevoxyl | $114 | $9,291167 claims |
| Antares Pharma, Inc.Xyosted | $55 | $7,62012 claims |
| AbbVieSynthroid | $115 | $3,39134 claims |
| IBSA Pharma Inc.Tirosint | $98 | $1,77013 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $99 | $98971 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Marrero
- Tilak MallikMarrero$51K
- Alejandra Riera GonzalezMarrero$7K
- Sarah KeslerMarrero$5K
- Amy VarugheseMarrero$3K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.